Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply

Pierce K H Chow1, Stephen P Hack2, Jessica H Spahn2

  • 1Division of Surgery and Surgical Oncology, National Cancer Centre Singapore and Duke-NUS Medical School, Singapore; Program in Translational and Liver Cancer Research, National Cancer Centre Singapore, Singapore 168583.

Lancet (London, England)
|August 17, 2024
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K